Abstract
The main objective of the study is to determine the pharmacist detection of drugdrug and drug-food interactions in patients receiving oral antineoplastic drugs (OADs). Descriptive, prospective study in a tertiary-care teaching hospital. The study population included patients who received OADs from the Outpatient Pharmacy of the hospital. The study population was attended by a pharmacist who checked potential interactions. The severity of interactions was evaluated using the summary of product characteristics of each drug and three different databases.
We included 219 patients with a total of 736 concomitant medications. A total of 34 drug-drug or food-drug interactions were recorded. The most common interaction detected was between erlotinib and ranitidine (major interaction). In 19 of the 34 interactions detected in the experimental group, the pharmacist prevented them from reaching the patient. Interactions were resolved by drug suspensions, drug changes, or changes in schedules always according to the attending physician or the patient. In the remaining 15 interactions, the doctor was not contacted because the interactions were considered to be of little relevance or because they only required surveillance. Hospital pharmacist can improve the patient's safety and the efficiency of oral cytostatic treatment by detecting and preventing drugdrug and drug-food interactions.
K E Y W O R D S
drug interactions, grapefruit, oral antineoplastic drug, pharmacist intervention of drug availability at receptor sites. Pharmacodynamic interactions usually refer to an interaction in which active compounds change each other's pharmacological effect. This effect can be synergistic, additive, or antagonistic (van Leeuwen, Gelder, & Mathijssen, 2014) .
The risk of drug interactions among cancer patients is high. This population is often polymedicated, elderly and treated by different physicians who might not be in regular contact with each other.
Moreover, cancer patients tend to use over the-counter drugs and herbal products without consulting their physicians and without realising the potential risk of interaction. Anticancer drugs have a narrow therapeutic range, so it is important to prevent drug interactions or detect them early (Carcelero, Anglada, Tuset, & Creus, 2013) .
In our field, not all patients who come to the Outpatient Pharmacy of the hospital to pick up medication are attended by a pharmacist, so the analysis of interactions is not carried out.
The main objective of the study is to determine the pharmacist detection of drug-drug and drug-food interactions in patients receiving OAD.
| ME THODS
We performed a descriptive, prospective study in a tertiary-care teaching hospital. This study was conducted over a period of 12 months. This study was approved by the Hospital Clínic of Barcelona's Clinical Research Ethics Committee. All patients gave their consent to participate.
Patients included were those who were visited by an oncologist or haematologist of the hospital and were prescribed an oral antineoplastic treatment. They carried an internal paper drug order with the prescription and came to the Outpatient Pharmacy of the hospital to collect the antineoplastic treatment. The study population was attended by a hospital pharmacist trained in oncology-haematology therapy.
Age, gender, Eastern Cooperative Oncology Group (ECOG) score, and diagnosis were recorded for all patients. This information was obtained from the electronic medical record (EMR).
The register of the concomitant medication was obtained during the interview with the patient and from the EMR where necessary (e.g. when the patient had forgotten).
Before dispensing the OAD, drug-drug interactions were checked for contraindicated or not recommended combinations using three different database: the Thomson Micromedex® version 2.0, the Medscape Interactions® (version ©2017 WebMD, LLC), and Uptodate, Inc®. The classification of interactions used by each database is shown in Table 1 . In case of discrepancy between the three databases and the technical data sheet, the recommendations were decided according to the pharmacist's criteria, based on the strictest recommendation. The summary of product characteristics of each drug was also reviewed. Pharmacist attending patients checked potential interactions, and a BPS Board Certified Oncology pharmacist reviewed all the findings. The interactions found were recorded in a specific form for the study and were added as a footnote with a recommendation on the computerised prescription/dispensation program, so that the attending physician could see it in case the patient was attended by another pharmacist or pharmacy technician in the future. If a contraindicated or important interaction was detected, the pharmacist phoned the attending physician as well. 
Severity Definition

| RE SULTS
The study population comprised 219 patients. Table 2 shows demographic characteristics of the patients and the number of patients for each OAD.
In total, 736 concomitant medications were registered. A total of 34 drug-drug or food-drug interactions were recorded. The most frequent interaction detected was between erlotinib and ranitidine (major interaction). The interactions observed and their severity are shown in Table 3 .
In 19 of the 34 interactions detected, the pharmacist prevented them from reaching the patient. These interactions were resolved by drug suspensions, drug changes, or changes in schedules always according to the attending physician or the patient. In three cases the patient usually ate or drank grapefruit, a potent intestinal CYP3A4 inhibitor that could increase exposure to the cytostatic he/she was taking. Accordingly, the patient was advised that during the treatment he or she should prevent grapefruit intake. In the rest of the cases (16 of 34) the drug involved in the interaction was replaced by another drug that did not interact or it was stopped by treating physician after being informed by the pharmacist at the time of antineoplastic dispensing. In the remaining 15 interactions, treating physician was not contacted because they were considered to be of little relevance or because they only required surveillance.
| D ISCUSS I ON
One of the clinical pharmacist's basic functions is to review the patient's regular medication to search for interactions with the aid of drugs databases. Consequently, most of pharmacist interventions are related to drug interactions (Girona Brumós, 2014).
Unfortunately, the review of drug interactions by the pharmacist is not always possible as not all patients who come to the Outpatient Pharmacy to pick up medication are attended by a pharmacist.
Pharmacy technicians or nurses can dispense medication as well, TA B L E 2 (Continued) however, they do not routinely analyse the presence of drug-drug interactions.
TA B L E 2 Demographic data
In the literature there are increasingly more studies of drug interactions between OADs and the patient's chronic medication, so it justifies the interest in verifying the potential interactions that can reach oncohaematological patients. Most of the studies published either analyse the interactions in a few OADs or use few databases. In our study, we included all the antineoplastics dispensed in the Outpatient Pharmacy and the three databases to which we have access.
One study to highlight is that of van Leeuwen et al. (van Leeuwen et al., 2013) , in which 1,359 potential interactions were detected in 426 patients. The medication collected were anticancer therapy (antineoplastic and hormonal), support therapy, and drugs to treat other pathologies. The authors used a specific program to detect interactions and classified them according to severity, bibliographic evidence and mechanism. In spite of not having absolute values, the authors indicate that the majority of the interactions occurred between the OADs and opioids and oral anticoagulants. In our study, we found two potential interactions in each group (3.6% and 5.88%).
It is worth mentioning that patients were prescribed low molecular weight heparin by the doctor, possibly to avoid an interaction.
In the study by Keller (Keller, Franquiz, Duffy, & Trovato, 2016 receiving oral chemotherapy (Backes, Griesbach, Wilhelm, & Plank, 2013; Vu, Wilson, Modlin, Kaster, & Mancini, 2011) . Given the frequency of potential drug interactions identified in the literature, patients can benefit significantly from pharmaceutical interventions focused on the prevention and management of drug interactions associated with OADs (Keller et al, 2016 ).
In conclusion, clinical pharmacist can improve the patient's safety and treatment efficiency by detecting and preventing drug-drug and drug-food interactions.
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